Table 3.
Effect of TRPV1 antagonists on the peak pressor and cardioaccelerator responses to stretch of triceps surae muscles
| TRPV1 Antagonist (Index) | Before Injection | After Injection | 95% CI | P Value | Cohen’s d |
|---|---|---|---|---|---|
| Capsazepine (10% ethanol/10% Tween 80; n = 8) | |||||
| MAP | 27 ± 13 | 25 ± 16 | [−9 5] | P = 0.29 | d = 0.18 |
| HR | 9 ± 9 | 7 ± 6 | [−6 2] | P = 0.25 | d = 0.40 |
| BPI | 417 ± 247 | 328 ± 208 | [−367 189] | P = 0.47 | d = 0.28 |
| Capsazepine (0.5% DMSO; n = 9) | |||||
| MAP | 38 ± 12 | 41 ± 15 | [−4 9] | P = 0.40 | d = 0.30 |
| HR | 9 ± 8 | 8 ± 8 | [−2 2] | P = 0.93 | d = 0.24 |
| BPI | 589 ± 378 | 397 ± 350 | [−905 −273] | P = 0.003 | d = 0.95 |
| Ruthenium red (n = 4) | |||||
| MAP | 47 ± 8 | 44 ± 19 | [−36 29] | P = 0.74 | d = 0.17 |
| HR | 4 ± 1 | 4 ± 2 | [−5 5] | P = 0.22 | d = 0.19 |
| BPI | 540 ± 174 | 468 ± 176 | [−274 130] | P = 0.22 | d = 0.42 |
| IRTX (n = 8) | |||||
| MAP | 39 ± 15 | 37 ± 17 | [−9 7] | P = 0.48 | d = 0.18 |
| HR | 5 ± 4 | 4 ± 3 | [−3 1] | P = 0.23 | d = 0.39 |
| BPI | 555 ± 220 | 549 ± 233 | [−113 103] | P = 0.47 | d = 0.50 |
Results are presented as means ± SD increase in mean arterial blood pressure (MAP, in mmHg), heart rate (HR, beats/min), or blood pressure index (BPI; measured as mmHg·s), evoked by passive stretch; n = sample size. Ninety-five percent confidence interval (CI) is presented as the lower and upper boundary of the interval containing the true value of the effect of the transient receptor potential vanilloid-1 (TRPV1) antagonist. IRTX, iodoresiniferatoxin.